GEFITINIB | N021399 | ASTRAZENECA UK LTD
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 3 | Active | Allist Pharmaceuticals, Inc. | 358 | 2019-05-30 → 2026-03 | |
| Phase 2 | Active | AstraZeneca | 247 | 2019-06-25 → 2025-05-06 | |
| Phase 1/2 | Active | Dana-Farber Cancer Institute | 48 | 2017-05-09 → 2027-10 | |
| Phase 1 | Active | Novartis Pharmaceuticals | 105 | 2018-01-29 → 2026-10-05 | |
| Phase 3 | Active | Eli Lilly and Company | 545 | 2015-05-06 → 2026-12 | |
| Phase 2 | Active | Novartis Pharmaceuticals | 29 | 2017-08-23 → 2027-07-30 | |
| Phase 3 | Active | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 337 | 2019-07-23 → 2026-09-30 | |
| Phase 3 | Active | Beta Pharma Shanghai | 369 | 2021-04-30 → 2025-12-30 | |
| Phase 2 | Recruiting | Hunan Province Tumor Hospital | 6,000 | 2020-04-16 → 2027-12-24 | |
| Phase 2 | Completed | AstraZeneca | 36 | 2003-02 → 2006-03 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Total Spending
$1.3M
Total Claims
198
Beneficiaries
29
Avg Cost/Unit
$235.13
Spending Trend
Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.
13 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Jun 21, 2005 | SUPPL -8 | View Letter (PDF) |
| Dec 2, 2004 | SUPPL -5 | View Letter (PDF) |
| Jun 7, 2004 | ORIG -1 | View Letter (PDF) |
| May 7, 2004 | SUPPL -3 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.